Duquesne Family Office

Activity in this selectionabrdn-686b29d8

By stage

Series C+3

Series B1

Biotech4

United States4

4 in this selection

Aug 10

Develops programmable epigenetic medicines to treat genetic diseases like FSHD

$90MSeries C

Role not disclosed

Jul 31

Developing best-in-class radiopharmaceuticals for cancer treatment

$70MSeries C

Role not disclosed

Jun 10

Develops ultrasound-mediated nonviral genetic medicines

$125MSeries B

Role not disclosed

Jan 28

Develops automated cell therapy manufacturing platforms

$257MSeries D

Role not disclosed